BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 15899046)

  • 1. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
    Boire G; Cossette P; de Brum-Fernandes AJ; Liang P; Niyonsenga T; Zhou ZJ; Carrier N; Daniel C; Ménard HA
    Arthritis Res Ther; 2005; 7(3):R592-603. PubMed ID: 15899046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
    Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
    Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies.
    Guzian MC; Carrier N; Cossette P; de Brum-Fernandes AJ; Liang P; Ménard HA; Boire G
    Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1624-32. PubMed ID: 20617532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.
    Jansen LM; van Schaardenburg D; van der Horst-Bruinsma I; van der Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2003 Aug; 30(8):1691-5. PubMed ID: 12913923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in early rheumatoid arthritis: Brasília cohort: results of a three-year serial analysis.
    da Mota LM; Santos Neto LL; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rev Bras Reumatol; 2011 Dec; 51(6):564-71. PubMed ID: 22124591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).
    Kastbom A; Strandberg G; Lindroos A; Skogh T
    Ann Rheum Dis; 2004 Sep; 63(9):1085-9. PubMed ID: 15308517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to cyclic citrullinated peptides in psoriatic arthritis.
    Bogliolo L; Alpini C; Caporali R; Scirè CA; Moratti R; Montecucco C
    J Rheumatol; 2005 Mar; 32(3):511-5. PubMed ID: 15742445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
    Panchagnula R; Rajiv SR; Prakash J; Chandrashekara S; Suresh KP
    J Clin Rheumatol; 2006 Aug; 12(4):172-5. PubMed ID: 16891919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
    Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
    Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.